शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
GLANDNSEGLAND PHARMA LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 6 Nov, 2026 · 16:33 IST

Consolidated Sep 2026 quarter: revenue up 2%, profit after tax up 58% year on year

Profit growth above 25%EBITDA margin compressionResults View source PDFExplain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

On a consolidated basis, for the quarter ended September 30, 2026, revenue from operations was Rs 18,335.88 million versus Rs 18,002.71 million a year earlier, up 1.8 percent, while profit after tax rose 58.3 percent to Rs 2,907.56 million from Rs 1,836.84 million. The operating margin before interest, tax, depreciation and amortisation fell sharply. The auditor's review was unmodified; half-year operating cash inflow was Rs 6,027.38 million.

Likely market impact

Profit growth is positive, but the sharp drop in operating margin may limit the benefit for shareholders and temper the share price reaction.

By the numbers

The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.